| Literature DB >> 28417918 |
Fatma Alzahraa M Gomaa1, Zeinab H Helal2,3, Mazhar I Khan4.
Abstract
The objective of this study was to evaluate the susceptibility of metallo-β-lactamase (MBL)-producing Acinetobacter baumannii (A. baumannii) clinical isolates to biocides. We also determined the prevalence and correlation of efflux pump genes, class 1 integron and MBL encoding genes. In addition, blaVIM, blaNDM-1, qacE and qacEΔ1 nucleotide sequence analysis was performed and compared to sequences retrieved from GenBank at the National Center for Biotechnology Information database. A. baumannii had a resistance rate to carbapenem of 71.4% and 39.3% and was found to be a MBL producer. The minimum inhibitory concentrations (MICs) of chlorhexidine and cetrimide were higher than the recommended concentrations for disinfection in 54.5% and 77.3% of MBL-positive isolates respectively and their MICs were significantly higher among qac gene-positive isolates. Coexistence of qac genes was detected in 68.1% and 50% of the isolates with blaVIM and blaNDM-1 respectively. There was a significant correlation between the presence of qac genes and MBL-encoding blaVIM and blaNDM-1 genes. Each of the blaNDM-1, blaVIM, qacE and qacEΔ1 DNA sequences showed homology with each other and with similar sequences reported from other countries. The high incidence of Verona integron-encoded metallo-β-lactamases (VIM) and New-Delhi-metallo-β-lactamase (NDM) and qac genes in A.baumannii highlights emerging therapeutic challenges for being readily transferable between clinically relevant bacteria. In addition reduced susceptibility to chlorhexidine and cetrimide and the potential for cross resistance to some antibiotics necessitates the urgent need for healthcare facilities to periodically evaluate biocides efficacy, to address the issue of antiseptic resistance and to initiate a "biocidal stewardship".Entities:
Keywords: Acinetobacter baumannii; MBL encoding genes; qac genes and biocides resistance
Year: 2017 PMID: 28417918 PMCID: PMC5488089 DOI: 10.3390/microorganisms5020018
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
The chemical agents, their starting concentrations and dilutions used for minimum inhibitory concentration (MIC) test.
| Chemical Agents | Recommended Dilution * | Starting Concentration | Dilutions |
|---|---|---|---|
| Chlorhexidine digluconate (CLX) | 0.0075% | 0.3% | 0.15%, 0.075%, 0.0375%, 0.0187%, 0.00937%, 0.00468%, 0.00234%, 0.00172% |
| Cetrimide | 0.075% | 3% | 1.5%, 0.75%, 0.375%, 0.187%, 0.094%, 0.046%, 0.023%. |
| Povidone-iodine (PVP-I2) | 5% | 10% | 5%, 2.5%, 1.25%, 0.625%, 0.3125%, 0.156%, 0.078% and 0.039% |
* According to manufacturer instructions.
List of primers used in the study.
| Gene Name | Sequence 5′-3′ | PCR Products | Reference | Annealing Temperature |
|---|---|---|---|---|
| Forward-CCCGAATTCATGAAAGGCTGGCTT | 350 bp | [ | 55 °C | |
| Forward-TAGCGAGGGCTTTACTAAGC | 300 bp | [ | 55 °C | |
| Forward-CAACTCCTTCGCCTATCCCG | 1058 bp | [ | 62 °C | |
| Forward-TAATGCTTTGATCGGCCTTG | 353 bp | [ | 60 °C | |
| Forward-GCATCCTCGGTTTTCTGG | 457 bp | [ | 60 °C | |
| Forward-CTACCGCAGCAGAGTCT TTG | 587 bp | [ | 55 °C | |
| Forward-GGCGGAATGGCTCATCACGA | 287 bp | [ | 58 °C | |
| Forward-GATGGTGTTTGGTCGCATA | 390 bp | [ | 52 °C | |
| Forward-AAAATCTGGGTACGCAAACG | 271 bp | |||
| Forward-TCGACACACCTTGGTCTGAA | 477 bp | |||
| Forward-TACAAGGGATTCGGCATCG | 570 bp |
Antimicrobial susceptibility patterns of Acinetobacter baumannii enrolled in the study.
| Antimicrobial Agent | |||
|---|---|---|---|
| S No (%) | I No (%) | R No (%) | |
| Amikacin | 9 (16.1) | 3 (5.3) | 44 (78.6) |
| Amoxicillin/clavulanic acid | 0 (0.0) | 0 (0.0) | 56 (100) |
| Cefazolin | 0 (0.0) | 0 (0.0) | 56 (100) |
| Cefepime | 4 (7.1) | 0 (0.0) | 52 (92.9) |
| Cefotaxime | 1 (1.8) | 5 (8.9) | 50 (89.3) |
| Cefotetan | 1 (1.8) | 2 (2.6) | 53 (94.6) |
| Ceftazidime | 4 (7.1) | 1 (1.8) | 51 (91.1) |
| Ceftriaxone | 5 (8.9) | 2 (2.6) | 49 (87.5) |
| Cefuroxime | 1 (1.8) | 1 (1.8) | 54 (96.4) |
| Imipenem | 16 (28.6) | 3 (5.3) | 37 (66.1) |
| Levofloxacin | 13 (23.2) | 7 (12.5) | 36 (64.3) |
| Meropenem | 16 (28.6) | 1 (1.8) | 39 (69.6) |
| Gifloatxacin | 8 (14.3) | 5 (8.9) | 33 (58.9) |
| Nitrofurantoin | 0 (0.0) | 0 (0.0) | 56 (100) |
| Ticarcillin/clavulanic acid | 6 (10.7) | 1 (1.8) | 49 (87.5) |
| Tobramycin | 16 (28.6) | 6 (10.7) | 34 (60.7) |
| Trimethoprim/sulfamethoxazole | 4 (7.1) | 0 (0.0) | 52 (92.9) |
| Tigicyclin | 56 (100) | 0 (0.0) | 0 (0.0) |
| Colistin | 56 (100) | 0 (0.0) | 0 (0.0) |
Antibiotic susceptibility, MICs of biocides and PCR results of metallo-β-lactamase (MBL)-positive A. baumannii isolates.
| Isolate Number | Type of Specimen | Biocide Resistance Genes | MIC of Biocide μg/mL | MBL Genes | Intl1 Gene | Antimicrobial Susceptibility | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PVP-I2 | CLX | Cetrimide | Ak | AMC | KZ | FEP | CTX | CTT | CAZ | CRO | CXM | GAT | IMP | MEM | LEV | F | TIM | TOB | SXT | TGC | CL | Category | MBL | ||||||||
| 1 | Throat Swab | + | + | - | 0.625 | 0.075 | 0.187 | - | + | + | R | R | R | R | R | R | R | R | R | I | R | R | I | R | R | R | R | S | S | MDR | + |
| 2 | Sputum | + | + | - | 0.625 | 0.0375 | 0.75 | - | + | + | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | S | S | XDR | + |
| 3 | Throat Swab | + | + | - | 1.25 | 0.009 | 0.049 | + | + | + | R | R | R | R | R | R | R | R | R | R | I | R | R | R | R | R | R | S | S | MDR | + |
| 4 | Blood | + | + | - | 1.25 | 0.0046 | 0.75 | + | + | + | I | R | R | R | R | R | R | R | R | R | R | R | S | R | R | R | R | S | S | MDR | + |
| 5 | Sputum | - | - | - | 1.25 | 0.009 | 0.098 | - | + | + | R | R | R | R | R | R | R | R | R | I | R | R | I | R | R | S | R | S | S | MDR | + |
| 6 | Pus | + | + | - | 0.625 | 0.0375 | 0.098 | + | + | + | S | R | R | R | R | R | R | R | R | R | R | R | I | R | R | S | S | S | S | MDR | + |
| 7 | Blood | + | + | - | 0.625 | 0.009 | 0.75 | - | + | + | R | R | R | R | R | R | R | R | R | I | I | R | I | R | R | I | R | S | S | MDR | + |
| 8 | Sputum | + | + | - | 1.25 | 0.0046 | 0.75 | + | + | + | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | S | S | XDR | + |
| 9 | Blood | + | + | - | 1.25 | 0.009 | 0.098 | + | + | + | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | S | S | XDR | + |
| 10 | Pus | - | + | - | 0.625 | 0.075 | 0.187 | + | + | + | S | R | R | R | R | R | R | R | R | S | R | R | R | R | R | R | R | S | S | MDR | + |
| 11 | Pus | - | + | - | 1.25 | 0.009 | 0.75 | + | + | + | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | S | S | XDR | + |
| 12 | Blood | - | + | - | 1.25 | 0.009 | 0.187 | + | + | + | R | S | R | R | R | R | R | R | R | S | R | R | S | R | R | R | R | S | S | MDR | + |
| 13 | Sputum | - | + | - | 1.25 | 0.0046 | 0.098 | + | + | + | R | R | R | R | R | R | R | R | R | R | I | R | R | R | R | R | R | S | S | MDR | + |
| 14 | Pus | + | + | - | 1.25 | 0.009 | 0.187 | + | + | + | S | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | S | S | MDR | + |
| 15 | Pus | - | - | - | 1.25 | 0.0023 | 0.049 | - | + | + | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | S | R | S | S | MDR | + |
| 16 | Blood | - | - | - | 0.039 | 0.0023 | 0.187 | + | + | + | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | S | S | XDR | + |
| 17 | Pus | - | - | - | 0.625 | 0.0046 | 0.049 | + | + | + | S | R | R | R | R | R | R | R | R | S | R | R | I | R | R | R | R | S | S | MDR | + |
| 18 | Sputum | - | + | - | 1.25 | 0.0046 | 0.187 | - | + | + | R | R | R | R | R | R | R | R | R | R | R | R | I | R | R | R | R | S | S | MDR | + |
| 19 | Chest Tube | - | - | - | 0.078 | 0.0046 | 0.187 | - | - | + | R | S | R | R | R | I | R | R | R | S | R | R | R | R | R | R | R | S | S | MDR | + |
| 20 | Chest Tube | + | + | - | 0.039 | 0.075 | 0.75 | + | + | + | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | S | S | XDR | + |
| 21 | Pus | - | - | - | 0.078 | 0.0023 | 0.049 | - | - | + | R | R | R | R | R | I | R | R | R | R | R | R | I | R | R | R | R | S | S | MDR | + |
| 22 | Nasal Swab | - | - | - | 0.625 | 0.0023 | 0.049 | - | - | + | S | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | S | S | MDR | + |
PVP-I2: Povidone-iodine; CLX: Chlorhexidine; AK: Amikacin; AMC: Amoxicillin/clavulanic acid; KZ: Cefazoline; FEP: Cefepime; CTX: Cefotaxime; CTT: Cefotetan: CAZ: Ceftazidime; CRO: Ceftriaxone; CXM: Cefuroxime; GAT: Gatifloxacin; IMP: Imipenem: MEM: Meropenem: LEV: Levofloxacin; F: Nitrofurantoin; TIM: Ticarcillin/Clavulinic; TOB: Tobramycin; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline; CL: Colistin; R: Resistant, S: Sensitive, I: Intermediate MDR: Multi drug resistant, XDR: Extensive drug resistant.
Figure 1Gel electrophoresis of the PCR amplified products of blaOxa51-like gene, intl1, MBL genes and Qac genes of A. baumannii isolates. (A) PCR amplified products of blaOxa51-like gene with 353 bp amplification fragment. M: 1 Kbp DNA ladder; (B) PCR amplified products of Intl1 gene with 475 bp amplification fragment. M: 100 bp DNA ladder; (C) PCR amplified products of balVIM gene with 390 bp amplification fragment. M: 100 bp DNA ladder; (D) PCR amplified products of blaNDM-1 gene with 287 bp amplification fragment. M: 100 bp DNA ladder; (E) PCR amplified products of qacE gene with 350 bp amplification fragment. M: 100 bp DNA ladder; (F) PCR amplified products of qacEΔ1 gene with 300 bp amplification fragment. M: 100 bp DNA ladder.
Correlation between biocides inhibitory concentration and the presence of qac genes.
| Chemical Agent | MIC μg/mL (%) | Number of Isolates ( | qac Genes | Chi-Square Tests | ||
|---|---|---|---|---|---|---|
| Positive | Negative | |||||
| Povidone-iodine | >50,000 (5%) | 0 | 0 | 0 | - | - |
| <50,000 (5%) | 22 | 15 | 7 | |||
| Chlorhexidine | >75 (0.0075%) | 12 | 11 | 1 | 6.712 | 0.0096 * |
| <75 (0.0075%) | 10 | 4 | 6 | |||
| Cetrimide | >750 (0.075%) | 17 | 14 | 3 | 6.924 | 0.0085 * |
| <50 (0.075%) | 5 | 1 | 4 | |||
* The result is significant when p < 0.05.
Correlation between qac genes and blaVIM and blaNDM-1 among MBL-positive A. baumannii isolates.
| MBL Genes | |||||
|---|---|---|---|---|---|
| qac Genes | Positive | Negative | Positive | Negative | |
| Positive | 15 | 0 | 11 | 4 | |
| Negative | 4 | 3 | 2 | 5 | |
| 0.0064 * | 0.0467 * | ||||
* The result is significant when p < 0.05.
Figure 2Phylogenetic analysis based on blaVIM gene sequences obtained from the nineteen A. baumannii isolates in this study and eight sequences retrieved from GenBank database. Phylogenetic tree was created with DNASTAR MegAlign by ClustalW (weighted) method. ACV; blaVIM gene isolated in this study and the other sequences were taken from Genbank.
Figure 3Phylogenetic analysis based on blaNDM-1 gene sequences obtained from the thirteen A. baumannii isolates in this study and seven sequences retrieved from GenBank database. Phylogenetic tree was created with DNASTAR MegAlign by ClustalW (weighted) method. NDM; blaNDM gene isolated in this study and the other sequences were taken from Genbank.
Figure 4Phylogenetic analysis based on qacΔE1 gene sequences obtained from the fifteen A. baumannii isolates in this study and four sequences retrieved from GenBank database. Phylogenetic tree was created with DNASTAR MegAlign by ClustalW (weighted) method. DE; qacEΔ1 gene isolated in this study and the other sequences were taken from Genbank.
Figure 5Phylogenetic analysis based on qacE gene sequences obtained from the ten A. baumannii isolates in this study and four sequences retrieved from GenBank database. Phylogenetic tree was created with DNASTAR MegAlign by ClustalW (weighted) method. E; qacE gene isolated in this study and the other sequences were taken from Genbank.